Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
Launched by PAMLAB, INC. · Dec 6, 2012
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
CerefolinNAC® is an orally administered prescription medical food, and is formulated as a combination of L-methylfolate calcium (as Metafolin®), methylcobalamin, and N-acetylcysteine. In a retrospective analysis, disease-delaying effects of Cerefolin®/CerefolinNAC® (CFLN) are examined in terms of cognition (measured by MCI Screen (MCIS)), and functional capacity (measured by Functional Assessment Staging Test (FAST)). - the treatment effect of CFLN on cognitive and functional measures, and on biomarker measures in patients with Alzheimer's disease and related disorders (ADRD).
The current ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • With a diagnosis of normal aging (NL), cognitive impairment or dementia not otherwise specified (CI/D), or ADRD
- • With at least one previous quantitative MRI (qMRI)
- • With at least one previous homocysteine level
- • Without homocysteinemia plus no past or current B12, folate or Cerefolin® treatment, OR with homocysteinemia plus past or current Cerefolin® treatment
- Exclusion Criteria:
- • Subjects who do not meet the inclusion criteria will be excluded from the study.
About Pamlab, Inc.
Pamlab, Inc. is a leading clinical trial sponsor dedicated to advancing innovative therapeutic solutions for patients with complex health conditions. With a strong focus on precision medicine, the company specializes in the development of nutraceuticals and pharmaceuticals aimed at improving patient outcomes in areas such as metabolic health and neurological disorders. Pamlab, Inc. leverages its expertise in research and development, along with strategic collaborations, to conduct rigorous clinical trials that adhere to the highest regulatory standards. Committed to scientific integrity and patient safety, Pamlab, Inc. strives to deliver meaningful advancements in healthcare through its robust pipeline of evidence-based products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newport Beach, California, United States
Patients applied
Trial Officials
William R Shankle, MS, MD, FACP
Principal Investigator
Shankle Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials